Focused Investors LLC Reduces Position in Johnson & Johnson (NYSE:JNJ)

Focused Investors LLC decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 0.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,160,250 shares of the company's stock after selling 10,000 shares during the period. Johnson & Johnson comprises 5.3% of Focused Investors LLC's portfolio, making the stock its 6th largest holding. Focused Investors LLC's holdings in Johnson & Johnson were worth $167,795,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Swedbank AB boosted its position in shares of Johnson & Johnson by 5.3% in the third quarter. Swedbank AB now owns 2,215,108 shares of the company's stock worth $358,980,000 after acquiring an additional 111,570 shares during the last quarter. Principal Financial Group Inc. increased its holdings in Johnson & Johnson by 10.5% in the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock valued at $562,723,000 after purchasing an additional 329,473 shares in the last quarter. United Bank raised its position in Johnson & Johnson by 5.6% in the third quarter. United Bank now owns 3,788 shares of the company's stock valued at $614,000 after purchasing an additional 202 shares during the period. Landscape Capital Management L.L.C. purchased a new stake in shares of Johnson & Johnson in the third quarter worth about $365,000. Finally, Eagle Asset Management Inc. grew its stake in shares of Johnson & Johnson by 22.1% in the third quarter. Eagle Asset Management Inc. now owns 57,612 shares of the company's stock valued at $8,957,000 after buying an additional 10,439 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Activity

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

JNJ stock traded up $0.62 during trading on Wednesday, hitting $161.64. 7,223,151 shares of the stock traded hands, compared to its average volume of 7,085,292. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a market cap of $389.54 billion, a price-to-earnings ratio of 24.31, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a 50 day simple moving average of $157.70 and a 200 day simple moving average of $156.14. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analysts' expectations of $22.44 billion. During the same period in the previous year, the firm earned $2.29 earnings per share. The company's revenue was up 5.3% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.07%. Johnson & Johnson's dividend payout ratio is 74.59%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Argus raised Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Barclays increased their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a research note on Tuesday, January 28th. Stifel Nicolaus lowered their target price on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a report on Thursday, January 23rd. Morgan Stanley lowered their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Finally, Leerink Partners reduced their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average price target of $171.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.